ACAD Q1 2021 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$107M+18.3% YoY

Gross Profit

$102M95.6% margin

Operating Income

-$67M-62.7% margin

Net Income

-$66M-62.4% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-11.9%

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$61M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$755M

Total Liabilities

$174M

Stockholders' Equity

$582M

Cash & Equivalents

$304M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$90M	+18.3%
Gross Profit	$102M	$85M	+19.7%
Operating Income	-$67M	-$90M	+25.4%
Net Income	-$66M	-$88M	+24.5%